drugset / Trial / NCT06090123
Drug-Drug Interaction (DDI) Study for TPN171H
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study was to assess the effect of rifampicin,a cytochrome P450 3A4 enzyme (CYP3A4) induction, on the pharmacokinetics (PK) of TPN171H in chinese healthy male subjects ,and assess the effect of itraconazole，cytochrome P450 3A4 enzyme (CYP3A4) induction on the PK of TPN171H in chinese healthy male subjects
Timeline
- Start
- 2020-01-01
- Primary completion
- 2020-04-27
- Completion
- 2020-09-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itraconazole | Small molecule | 200 mg | — |
| Subject | Rifampin | Small molecule | 600 mg | — |
| Subject | TPN171H | Unknown | 10 mg | — |
| Subject | TPN171H | Unknown | 20 mg | — |